Daewoong Pharmaceutical, 16,459 Shares Net Bought by Individuals in Last 5 Days... Stock Price 123,000 Won (+8.37%)

As of 9:30 AM on the 4th, Daewoong Pharmaceutical is trading at 123,000 KRW, up 8.37% from the previous day. The trading volume is 488,230 shares, which is 89.0% of the previous day's volume. Daewoong Pharmaceutical is known as a leading pharmaceutical company manufacturing and selling drugs such as Urusa and Albis.

On December 1st, Shin Jae-hoon, a researcher at Hanwha Investment & Securities, stated, "The result of the ITC (International Trade Commission) lawsuit between Daewoong Pharmaceutical and Medytox regarding botulinum toxin has been reconfirmed for December 16th. Attention is focused on how the previously recommended 10-year import ban from the preliminary results will change. Various scenarios are expected, including a reduction in the import ban period, damages to Evolus, or a ruling different from the preliminary results. Ultimately, on December 16th, the conclusion of this long battle will be reached, which is expected to resolve uncertainties for both companies." He set the target price for Daewoong Pharmaceutical at 120,000 KRW.

Over the past five days, individual investors have net purchased 16,459 shares of Daewoong Pharmaceutical, while foreigners and institutions have net purchased 5,410 shares and net sold 9,390 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.